Each year, Accelerate Brain Cancer Cure hosts a scientific meeting to give researchers, investors, policy leaders, and industry leaders the chance to discuss progress in brain cancer research. The meeting serves as a catalyst for innovation and allows scientists to form collaborations with biotechnology and pharmaceutical companies that can drive discoveries from lab to the clinic.
2008 Annual Scientific Meeting
Agenda
Thursday, November 13 | |
Meeting Location: | Smithsonian Institution Building, the Castle 1000 Jefferson Drive, SW Washington, DC |
8:30 – 9:00 AM | Welcome, Chairman’s Remarks and Introductions Smithsonian Castle, Castle Common |
Steve Case Chairman, Accelerate Brain Cancer Cure |
|
Max Wallace Chief Executive Officer, Accelerate Brain Cancer Cure |
|
9:00 – 10:30 AM | Panel 1. Genomic analyses of GBM: What have we learned from this landmark work and where can it lead us? |
Introduction by Dr. Francis Collins Former Director and now Special Volunteer, National Human Genome Research Institute | |
Moderated by Dr. Francis Collins | |
Dr. Lynda Chin Associate Professor, Department of Dermatology, Harvard Medical School and Department of Medical Oncology , Dana-Farber Cancer Institute |
|
Dr. Paul Mischel Professor, Department of Pathology and Laboratory Medicine and Molecular Medicine Pharmacology, David Geffen UCLA School of Medicine and Vice President, American Society of Clinical Investigation |
|
Dr. Will Parsons Assistant Professor, Pediatric Hematology-Oncology, Baylor College of Medicine, and Assistant Professor (visiting), Kimmel Cancer Center at Johns Hopkin | |
Discussion to follow. | |
- 15 min. break - | |
10:45 – 12:15 PM | Panel 2. Translating the GBM genome into the clinic: Short-term and long-term implications for patient care and new drug development. |
Moderated by Dr. Susan Chang Professor of Neurological Surgery, UCSF |
|
Dr. Alfred Yung Chair, Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center |
|
Dr. David Parkinson President and Chief Executive Officer, Nodality, Inc. |
|
Dr. Philippe Bishop Vice President, Clinical Development, Avastin |
|
1:00 – 2:30 PM | Panel 3. Discussion of the Most Current Clinical Approaches to Treating GBM. |
Moderated by Dr. David Agus Research Director, Louis Warschaw Prostate Cancer Center Director, Spielberg Family Center for Applied Proteomics, Cedars-Sinai Medical Center |
|
- 15 min. break - | |
2:45 – 4:00 PM | Panel 4. GBM and the National Agenda: New initiatives at the NCI and the introduction of a new healthcare bill in Congress. |
Moderated by Max Wallace | |
Dr. Carolyn Compton Director, Office of Biorepositories and Biospecimen Research, National Cancer Institute |
|
Dr. Kavita Patel Deputy Staff Director of the Senate Health, Education, Labor and Pensions Committee |
|
Dr. Ken Buetow Associate Director for Biomedical and Information Technology, National Cancer Institute |
|
5:00 – 6:00 PM | Cocktail Reception Indian Treaty Room The White House Complex The Eisenhower Executive Office Building 1600 Pennsylvania Avenue Washington, DC |
Friday, November 14 | |
8:30 – 9:45 AM | Panel 5. Brain cancer and the physical sciences. |
Dr. Sanjay Kumar Assistant Professor of Bioengineering, University of California, Berkeley |
|
Dr. Robert Urban Executive Director, Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology |
|
9:45 – 10:45 AM | Closing Keynote Address |
“A Systems Approach to Brain Cancer: Science, Technology and Strategic Partnerships” | |
Dr. Leroy Hood Founder and President, Institute for Systems Biology |
|
10:45 – 11:00 AM | Closing Remarks |
Steve Case Chairman, Accelerate Brain Cancer Cure |